Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity

被引:47
作者
Nazeyrollas, P
Prévost, A
Baccard, N
Manot, L
Devillier, P
Millart, H
机构
[1] Fac Med, Pharmacol Lab, F-51095 Reims, France
[2] Inst Jean Godinoi, F-51100 Reims, France
关键词
amifostine; doxorubicin; isolated rat heart; cardiotoxicity; cardioprotection;
D O I
10.1007/s002800050888
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: To determine the effects of amifostine on an isolated perfused rat-heart model and its protective activity With regard to cardiotoxic doxorubicin perfusion. Methods: Langendorff constant-pressure isolated rat-heart preparations were used to analyze the effects of the drugs during a 40-min period of perfusion after a 20-min stabilization interval. The first study was conducted with amifostine alone (controls and 10(-6), 10(-5), and 10(-4) M amifostine; n = 6 in each group). The second study was conducted with amifostine and doxorubicin (controls, 2.5 x 10(-5) M doxorubicin, 2.5 x 10(-5) M doxorubicin and 10(-5) M amifostine, and 2.5 x 10(-5) n doxorubicin and 10(-4) M amifostine, n = 4 in each group). Results: Amifostine had no significant effect on hemodynamic parameters at 10(-6), 10(-5), and 10(-4) M concentrations. However, amifostine increased the coronary flow expressed as a percentage +/- SEM of the baseline flow as follows: 82 +/- 4% for controls, 95 +/- 6% for 10(-6) M amifostine, (P = 0.13), 111 +/- 4% for 10(-5) M amifostine (P < 0.01), and 104 +/- 3% for 10(-6) M amifostine (P < 0.01). When we commenced an amifostine perfusion 20 min in advance of and then during a 40-min perfusion with doxorubicin, at a cardiotoxic concentration of 2.5 x 10(-5) M the left ventricular pressures (LVDP, expressed as percentages +/- SEM of the baseline LVDP before doxorubicin) were 55 +/- 3% for the doxorubicin controls, 68 +/- 2% for duxorubicin with 10(-5) M amifostine (P = 0.05), and 80 +/- 3% for doxorubicin with 10(-4) M amifostine (P < 0.01). Whether this protective effect might be related to the known free-radical-scavenging activity of amifostine remains to be determined. Conclusion: On a Langendorff-type model of rat heart, 10(-5) and 10(-4) M amifostine alone induced a coronary dilation and, when associated with a cardiotoxic concentration of 2.5 x 10(-5) M doxorubicin, 10(-5) and 10(-4) M amifostine displayed a cardioprotective effect.
引用
收藏
页码:227 / 232
页数:6
相关论文
共 23 条
[1]
USE OF THE ISOLATED PERFUSED HEART FOR EVALUATION OF CARDIAC TOXICITY [J].
ANDERSON, PG ;
DIGERNESS, SB ;
SKLAR, JL ;
BOOR, PJ .
TOXICOLOGIC PATHOLOGY, 1990, 18 (04) :497-510
[2]
EFFECT OF DOXORUBICIN ON POSTREST CONTRACTION IN ISOLATED RAT HEARTS [J].
ASAYAMA, J ;
TANAKA, T ;
TATSUMI, T ;
NAKAGAWA, C ;
KOBARA, M ;
MATOBA, S ;
OHTA, B ;
INOUE, D ;
NAKAGAWA, M .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 26 (05) :693-697
[3]
BHANUMATHI P, 1992, BIOCHEM ARCH, V8, P335
[4]
ANTHRACYCLINE-INDUCED TENSION IN PERMEABILIZED CARDIAC FIBERS - EVIDENCE FOR THE ACTIVATION OF THE CALCIUM RELEASE CHANNEL OF SARCOPLASMIC-RETICULUM [J].
BOUCEK, RJ ;
BUCK, SH ;
SCOTT, F ;
OQUIST, NL ;
FLEISCHER, S ;
OLSON, RD ;
OKEDIJI, E .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1993, 25 (03) :249-259
[5]
CALABROJONES PM, 1988, CANCER RES, V48, P3634
[6]
ACUTE CARDIOVASCULAR AND AUTONOMIC EFFECTS OF WR-2721 - RADIOPROTECTIVE COMPOUND [J].
CALDWELL, RW ;
HEIFFER, MH .
RADIATION RESEARCH, 1975, 62 (01) :62-69
[7]
DORR RT, 1994, P AN M AM SOC CLIN, V13, P435
[8]
APPARATUS FOR STUDY OF VENTRICULAR FUNCTION AND METABOLISM IN ISOLATED PERFUSED RAT HEART [J].
FALLEN, EL ;
ELLIOTT, WC ;
GORLIN, R .
JOURNAL OF APPLIED PHYSIOLOGY, 1967, 22 (04) :836-&
[9]
DOXORUBICIN TOXICITY IN PERFUSED RAT-HEART - DECREASED CELL-DEATH AT LOW OXYGEN-TENSION [J].
GANEY, PE ;
CARTER, LS ;
MUELLER, RA ;
THURMAN, RG .
CIRCULATION RESEARCH, 1991, 68 (06) :1610-1613
[10]
WR-2721 PROTECTS AGAINST THE HEMATOLOGIC TOXICITY OF CYCLOPHOSPHAMIDE - A CONTROLLED PHASE-II TRIAL [J].
GLOVER, D ;
GLICK, JH ;
WEILER, C ;
HUROWITZ, S ;
KLIGERMAN, MM .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (04) :584-588